Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, Vanlemmens L, Leheurteur M, Lévy C, Laborde L, Uwer L, D'hondt V, Berchery D, Lorgis V, Ferrero JM, Perrocheau G, Courtinard C, Mouret-Reynier MA, Velten M, Breton M, Parent D, Chabaud S, Robain M, Bachelot T. Le Saux O, et al. Among authors: chabaud s. Eur J Cancer. 2019 Sep;118:131-141. doi: 10.1016/j.ejca.2019.06.014. Epub 2019 Jul 19. Eur J Cancer. 2019. PMID: 31330488
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Cassier PA, Chabaud S, Trillet-Lenoir V, Peaud PY, Tigaud JD, Cure H, Orfeuvre H, Salles B, Martin C, Jacquin JP, Agostini C, Guastalla JP, Pérol D, Bachelot T. Cassier PA, et al. Among authors: chabaud s. Breast Cancer Res Treat. 2008 May;109(2):343-50. doi: 10.1007/s10549-007-9651-3. Epub 2007 Jul 5. Breast Cancer Res Treat. 2008. PMID: 17611792 Clinical Trial.
Development of a rule based prognostic tool for HER 2 positive breast cancer patients.
Lisboa PJ, Etchells TA, Jarman IH, Aung MS, Chabaud S, Bachelot T, Perol D, Gargi T, Bourdès V, Bonnevay S, Négrier S. Lisboa PJ, et al. Among authors: chabaud s. Annu Int Conf IEEE Eng Med Biol Soc. 2007;2007:5416-9. doi: 10.1109/IEMBS.2007.4353567. Annu Int Conf IEEE Eng Med Biol Soc. 2007. PMID: 18003233
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Ray-Coquard I, et al. Among authors: chabaud s. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/0008-5472.CAN-08-3845. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549917 Free PMC article.
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.
Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Ménétrier-Caux C. Manuel M, et al. Among authors: chabaud s. Oncoimmunology. 2012 Jul 1;1(4):432-440. doi: 10.4161/onci.19545. Oncoimmunology. 2012. PMID: 22754761 Free PMC article.
234 results